Cargando…
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
BACKGROUND: To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC) assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall and progression- free patient survival. METHODS: Thirty-nine consecutive patients with mR...
Autores principales: | Farnebo, Jacob, Grybäck, Per, Harmenberg, Ulrika, Laurell, Anna, Wersäll, Peter, Blomqvist, Lennart K, Ullén, Anders, Sandström, Per |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064288/ https://www.ncbi.nlm.nih.gov/pubmed/24906441 http://dx.doi.org/10.1186/1471-2407-14-408 |
Ejemplares similares
-
Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT
por: Farnebo, Jacob, et al.
Publicado: (2016) -
The preoperative localisation of small parathyroid adenomas improves when adding Tc-99m-Sestamibi SPECT to multiphase contrast-enhanced CT
por: Sandqvist, Patricia, et al.
Publicado: (2021) -
Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018) -
Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma
por: Frödin, Magnus, et al.
Publicado: (2017) -
Perivascular Neuropilin‐1 expression is an independent marker of improved survival in renal cell carcinoma
por: Morin, Eric, et al.
Publicado: (2020)